Melanie Aitken

Melanie Aitken is the Managing Principal of Bennett Jones (US) LLP. She is also co-head of the competition and foreign investment practice of Bennett Jones. She specializes in global antitrust and competition law and litigation.

Melanie served as Canada’s Competition Commissioner, in charge of the Canadian Competition Bureau from 2009 to 2012, having previously served as the Senior Deputy Commissioner leading merger review from 2006 to 2009.

While serving as Commissioner, Melanie led many high-profile civil and criminal matters and worked extensively with leaders of international antitrust authorities around the world on enforcement and policy cases, holding leadership roles in key international organizations, such as the Steering Committee of the International Competition Network.

Melanie was a partner at Bennett Jones and Davies Ward Philips & Vineberg before joining the Bureau in 2005. She has acted as counsel in the Supreme Court of Canada and represented the merging parties in Canada’s leading efficiencies case, Superior Propane. Melanie has an active antitrust advisory, trial and commercial practice, representing major Canadian and US companies in significant matters across a broad range of industries.

Melanie is a frequent speaker and commentator on competition issues, and has taught as an Adjunct Professor at Osgoode Hall and Queen’s Law Schools. She is active on the C.D. Howe Institute’s Competition Policy Council, and sits on the Advisory Boards of the Global Antitrust Institute, Schulich School of Business (Toronto, Canada), and W@CompetitionAmericas, and has been appointed a Fellow of the American Bar Foundation. Melanie also serves as a non-governmental advisor to the International Competition Network.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More